Olix Logo.jpg
OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Androgenic Alopecia
June 09, 2021 10:00 ET | OliX Pharmaceuticals
SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and LGC, a global leader in the life...
Olix Logo.jpg
OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
June 07, 2021 08:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, June 07, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has...
Olix Logo.jpg
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics
May 24, 2021 08:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of...
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
February 10, 2021 17:45 ET | OliX Pharmaceuticals
Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11 SUWON, Republic of Korea, Feb. 10, 2021 (GLOBE NEWSWIRE) --...
Olix Logo.jpg
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics
February 08, 2021 07:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, Feb. 08, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX...
Olix Logo.jpg
OliX Pharmaceuticals to Present at 2021 ICR Conference
January 06, 2021 07:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
Olix Logo.jpg
OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally
December 01, 2020 07:00 ET | OliX Pharmaceuticals
Capital to fund construction of RNA synthesis GMP facility in San DiegoSupports company’s goal of having 10 programs entered into clinical trials by 2024 SUWON, Republic of Korea, Dec. 01, 2020 ...
Olix Logo.jpg
OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars
October 30, 2020 10:02 ET | OliX Pharmaceuticals
Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to-datePhase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November...
Olix Logo.jpg
OliX Pharmaceuticals to Present at OPT Congress and BIO-Europe
October 20, 2020 13:31 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, Oct. 20, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder...
Olix Logo.jpg
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
October 07, 2020 09:00 ET | OliX Pharmaceuticals
Companies to broaden their existing partnership on Age-related Macular Degeneration (AMD) treatmentsOliX grants Théa worldwide rights excluding Asia-Pacific on OLX301A and OLX301D, targeting dry/wet...